
"Sector" = median of Healthcare across 84 companies
The Cigna Group is a global health services company that provides health insurance, pharmacy benefits, and wellness solutions. Its core operations include medical coverage for employers, individuals, and government programs, as well as specialty services like dental, vision, and behavioral health. Cigna also operates a large pharmacy benefit manager (PBM) through its Express Scripts subsidiary, which manages drug costs for clients.
Revenue is generated primarily from premiums (health insurance) and service fees (PBM and administrative services). The company earns premiums from employer-sponsored plans, individual policies, and government contracts (Medicare, Medicaid). The PBM segment generates revenue through drug rebates, network fees, and mail-order pharmacy sales. In recent quarters, quarterly revenue has ranged from $67B to $72B, with net income around $1.2B-$1.9B.
Cigna competes in the highly regulated healthcare plans industry, alongside UnitedHealth, Anthem (Elevance), and Humana. It is positioned as a diversified health insurer with a strong PBM, offering integrated medical and pharmacy benefits. The company has a moderate market cap of $71.7B, low P/E of 11.6, and high free cash flow yield of 10.2%, indicating efficient operations. Its debt-to-equity is elevated due to the Express Scripts acquisition, but cash flow supports debt service.
Cigna serves a broad customer base including large employers, mid-sized businesses, government entities, and individuals. Its primary geographic market is the United States, where it covers over 19 million medical members and 100+ million pharmacy customers. The company also has international operations in select markets. The target audience is cost-conscious employers and individuals seeking integrated health and pharmacy benefits.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Latest saved period: March 2026 · 2026-03-31
Cash dividends by ex-date, not an investment recommendation.
| Ex-date | Amount | Payment date | Period |
|---|---|---|---|
| Jun 4, 2026 | $1.56 | Jun 18, 2026 | — |
| Mar 5, 2026 | $1.56 | Mar 19, 2026 | Quarterly |
| Dec 4, 2025 | $1.51 | Dec 18, 2025 | Quarterly |
| Sep 4, 2025 | $1.51 | Sep 18, 2025 | Quarterly |
| Jun 3, 2025 | $1.51 | Jun 18, 2025 | Quarterly |
| Mar 5, 2025 | $1.51 | Mar 20, 2025 | Quarterly |
| Dec 4, 2024 | $1.40 | Dec 19, 2024 | Quarterly |
| Sep 4, 2024 | $1.40 | Sep 19, 2024 | Quarterly |
| Jun 4, 2024 | $1.40 | Jun 20, 2024 | Quarterly |
| Mar 5, 2024 | $1.40 | Mar 21, 2024 | Quarterly |
| Dec 5, 2023 | $1.23 | Dec 21, 2023 | Quarterly |
| Sep 5, 2023 | $1.23 | Sep 21, 2023 | Quarterly |
| Jun 6, 2023 | $1.23 | Jun 22, 2023 | Quarterly |
| Mar 7, 2023 | $1.23 | Mar 23, 2023 | Quarterly |
| Dec 5, 2022 | $1.12 | Dec 21, 2022 | Quarterly |
| Sep 6, 2022 | $1.12 | Sep 22, 2022 | Quarterly |
| Jun 7, 2022 | $1.12 | Jun 23, 2022 | Quarterly |
| Mar 8, 2022 | $1.12 | Mar 24, 2022 | Quarterly |
| Dec 6, 2021 | $1.00 | Dec 22, 2021 | Quarterly |
| Sep 7, 2021 | $1.00 | Sep 23, 2021 | Quarterly |
| Jun 7, 2021 | $1.00 | Jun 23, 2021 | Quarterly |
| Mar 9, 2021 | $1.00 | Mar 25, 2021 | Quarterly |
| Mar 9, 2020 | $0.04 | Apr 9, 2020 | Annual |
| Mar 8, 2019 | $0.04 | Apr 10, 2019 | Annual |
Wrqti brings The Cigna Group data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Healthcare sector you can compare with The Cigna Group:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: March 2026.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.